Birchview Capital, LP Biocryst Pharmaceuticals Inc Transaction History
Birchview Capital, LP
- $108 Million
- Q3 2024
A detailed history of Birchview Capital, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Birchview Capital, LP holds 40,000 shares of BCRX stock, worth $306,800. This represents 0.28% of its overall portfolio holdings.
Number of Shares
40,000
Previous 40,000
-0.0%
Holding current value
$306,800
Previous $247,000
23.08%
% of portfolio
0.28%
Previous 0.25%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$156 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$153 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$91 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$69.7 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$67.9 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.43B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...